Kornimate/medical-research-clean huggingface dataset:
177lu-psma-i＆t psma radioligand therapy in metastatic castration-resistant prostate cancer

Conditions: Metastatic Castration-resistant Prostate Cancer

Summary: the purpose of this study is to determine the safety and efficacy of 177 lu -labeled psma ligand(psma-i＆t) in the treatment of mcrpc in asianethics.

prostate specific membrane antigen(psma) targeted therapy brings new hope to the patients with metastatic castration-resistant prostate cancer (mcrpc). here, we reported the safety and efficacy of 177 lu -labeled psma ligand(psma-i＆t) in the treatment of mcrpc in asianethics. prostate cancer is the most common cancer diagnosed in older men with recent data .psma is a type ii transmembrane glycoprotein，overexpressed up to 100 to 1000 times higher than normal prostate cells in prostate cancer cells and is correlated with higher-grade cancers, metastatic disease and hormone refractory disease. lutetium-177 (177lu)-psma (lupsma) is a novel and highly targeted systemic rlt for progressive mcrpc. upon binding of lupsma to the cell membrane, endocytosis is triggered, concentrating the tumouricidal effects of the radioisotope activity internally within malignant cells. this is a single-institution, single-arm phase 2 clinical trial. patients will receive prlt treatment. the follow-up period was followed up to assess safety and effectiveness.

Eligibility criteria:
entry criteria 1. ecog score: 0-1 point 2. lymph and skeletal metastases or visceral metastases that cannot be removed surgically 3. the disease continues to progress after treatment with adt, chemotherapy, radiotherapy, or abiraterone and emzaludine 4.68ga psma-11 pet / ct showed that there was significant radioactivity uptake in tumor tissues and metastases \[suvmax\> 7\], which was significantly higher than that in the liver. exclusion criteria 1. previous treatment with any of the following within 6 months of randomization: strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223, hemi-body irradiation. previous psma-targeted radioligand therapy is not allowed. 2. hemoglobin\<80g/l;hemameba\<2.5×109/l;thrombocyte\<70g/l 3. glomerular filtration rate\<50ml/min 4. serum creatinine\>130umol/l;total bilirubin\>2mg/l;albumin\<30g/l. 5. international normalized ratio（inr）\>1,5 6. alanine aminotransferase, aspartate aminotransferase is 5 times larger than normal value

Keywords: 177lu-psma-i&t prostate cancer
efficacy of teas on prevention of propofol injection pain in children

Conditions: Injection Site

Summary: the purpose of this study is to determine the efficacy of transcutaneous electrical acupoint stimulation for the prevention of propofol injection pain in children.

pain from the injection of propofol is a common side effect during anesthetic practice. various methods have been used to reduce this pain. this prospective, randomized study was designed to determine the efficacy of transcutaneous electrical acupuncture point stimulation in reducing propofol injection pain in children.

Eligibility criteria:
inclusion criteria: * asa i-ii and aged 6-13 years patents who will undergo elective surgery under general anesthesia exclusion criteria: * patients with propofol allergy * patients who have renal, hepatic, cardiac, neurological, psychiatric disease * cardiac and cranial surgery * pacemaker, * emergency surgery and patients requiring rapid serial induction
interest of levosimendan preconditioning for cardiac surgery under cec in heart failure patients with impaired ejection fraction

Conditions: Levosimendan; Cardiac Surgery; Heart Failure With Reduced Ejection Fraction

Summary: levosimendan, a drug with inotropic, vasodilatory and myocardial protective properties, has been proposed for the prevention and treatment of postoperative low cardiac output syndrome in cardiac surgery. despite preliminary studies with promising results, large randomized controlled trials aimed at demonstrating the benefits of levosimendan did not show superiority over placebo in this indication. however, in these studies, the infusion was neither performed at the maximum dosage nor during the 24 hours preceding the surgery, but mainly at the very beginning of the operation. however, post hoc analyses showed a reduction in mortality and in the occurrence of low cardiac output syndrome in the subgroup of patients who had undergone isolated coronary artery bypass grafting, in contrast to those who had undergone valvular or combined surgery. another recent study suggests that under similar conditions, preconditioning with levosimendan started 48 hours before surgery reduces the length of stay in intensive care and the average cost of hospitalization. there are no formal recommendations on the prophylactic use of levosimendan in cardiac surgery for heart failure patients with impaired lvas. however, the france-levo registry, a multicenter observational study requested by the has, has shown that in real practice there is a place for preconditioning with levosimendan, which is used in this indication for 7% of the patients in the registry. the cardiovascular surgery and transplantation department of the nancy brabois university hospital, which actively participated in the france-levo registry, is one of the cardiac surgery centers that uses this practice, as is the university hospital of rouen. it is interesting to be able to evaluate retrospectively whether levosimendan preconditioning has a positive impact on the postoperative prognosis of patients and more particularly on the reduction of the length of stay in critical care and in hospital compared to standard management.


Eligibility criteria:
inclusion criteria: * patients with heart failure impaired lvef (\< 40%), who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at different university hospital in france exclusion criteria: * initiation of levosimendan \> 48 hours or \< 24 hours before surgery ecmo pre- or post-op

Keywords: levosimendan cardiac surgery cardiopulmonary bypass heart failure with reduced ejection fraction
effects of nebivolol on subclinical left ventricular dysfunction: a comparative study against metoprolol

Conditions: Primary Arterial Hypertension

Summary: summary: * study title: effects of nebivolol on subclinical left ventricular dysfunction. a comparative study against metoprolol. (enesys study) * study phase: 3 * study design (parallel, cross-over, etc.), randomisation and blinding procedures, type of control (placebo or active): randomised, parallel, active-controlled, open label * study treatment(s)/drug(s): nebivolol versus metoprolol * patients: * characteristics: patients with hypertension and left ventricular hypertrophy * planned total number: 50 * study duration: * total enrolment period (months): 18 * treatment period (months): 6 * follow up period (months): 6 * total study duration (months): 24 * number of centres: 1 * country(ies): romania (ro)

study objectives 1. primary: * longitudinal myocardial velocities at rest (assessed by tissue doppler echocardiography) * systolic functional reserve (calculated as the absolute and relative increase of the myocardial systolic velocities at peak stress from rest) * brain natriuretic peptide (bnp, nt-pro bnp) after a 6-months period of treatment with nebivolol versus metoprolol. an improvement of more than 20% of the myocardial resting velocities of systolic functional reserve is considered to be clinically relevant. the working hypothesis is that the improvement of subclinical left ventricular dysfunction after 6 months of treatment is going to be greater in patients who receive nebivolol than in those who receive metoprolol. 2. secondary: * global systolic function (ejection fraction) * radial myocardial velocities * right ventricular function * global diastolic function * left ventricular mass index

Eligibility criteria:
inclusion criteria: * aged 18 years or older, men and women, hospitalized and outpatients * with a history of primary arterial hypertension * with a daytime ambulatory blood pressure \>140 and/or \>90 mm hg * with left ventricular hypertrophy: lvmi \> 125 g/m2 for men, and \> 110 g/m2 for women, by devereux formula, as recommended by the esh-esc guidelines (14) * in sinus rhythm * consented, by signing the informed consent exclusion criteria: * severe arterial hypertension (systolic blood pressure \> 180 mm hg and/or diastolic blood pressure \> 110 mm hg) * any history of coronary heart disease (stable angina, acute coronary syndromes, myocardial infarction) * any history of cerebrovascular disease * renal impairment (creatinine \> 1.5 mg% for men, \> 1.4 mg% for women) * left ventricular global systolic dysfunction (ef \< 45%) * more than mild valvar (mitral or aortic) regurgitation * hypertrophic cardiomyopathy * pericarditis * cor pulmonale * pregnancy or lactating women * any significant co-morbidities * contraindication to beta-blocker therapy * concomitant treatment with other beta-blockers * participation to another investigational study in the last 3 months

Keywords: arterial hypertension
sms-based lifestyle intervention for patients with liver cirrhosis with previous hepathic encephalopathy

Conditions: Liver Cirrhosis, Alcoholic

Summary: to investigate whether simple reminders about healthy lifestyle sent via mobile phone text messages can improve the liver cirrhosis severity and prognosis (as assessed by the meld score supported by the child-pugh score) among patients with liver cirrhosis that have been through a 12-week supervised and facility-based physical exercise training program and in-patient rehabilitation.

physical exercise and other interventions focused on lifestyle factors have not only the potential to increase physical functioning and capacity, but also to affect fundamental aspects of disease, increase quality of life, and may even increase survival in patients with liver cirrhosis. instruction and advice about a healthy lifestyle and physical activity are attractive as it limits time spent on supervised rehabilitation at an outpatient clinic. further, self-management can be attractive to society as it can conserve health care resources. however, instructions and advice can only be effective if the patients adhere to them, and there is a need for initiatives that enhance the motivation to follow the advice and change undesirable behaviours. mobile phone short-message service (sms) messages are increasingly used to deliver interventions and enhance healthy behaviour. the technology is simple, cost-effective, can be automated, and can reach any mobile phone owner. in a recent systematic review, sms-messages have been shown effective in a broad range of healthy behaviours, which was also highlighted in a randomized trial showing positive effects of lifestyle-focused sms-messages on cardiovascular risk factors in patients with coronary heart disease. an sms-message-based lifestyle intervention therefore seems like a feasible and effective means of enhancing motivation to follow advice about healthy lifestyle and physical activity among patients with liver cirrhosis.

Eligibility criteria:
inclusion criteria: 1. adult, i.e. age 18 years or above. 2. is attending the liver cirrhosis rehabilitation clinic at bispebjerg hospital; i.e., has alcohol-induced liver cirrhosis or hepatorenal syndrome and has at least once experienced severe decompensation in the form of hepatic encephalopathy or variceal haemorrhage. 3. has attended at least 50% of the scheduled sessions in the 12 week run-in physical exercise program 4. is the owner of a mobile phone capable of receiving sms-messages 5. has signed informed consent 6. reads and speaks danish exclusion criteria: 1. any condition that in the opinion of the investigator puts an otherwise eligible participant at increased risk by participation or otherwise make the person unfit for participation
the identification and characterization of autonomic dysfunction in migraineurs with and without auras

Conditions: Migraine

Summary: this is a study to compare subject response and symptoms resulting from administration of three clinical assessments. \* the 3 assessments are 1. passive upright tilt table testing, 2. quantitative sudomotor axon reflex testing (qsart)and 3. punch biopsy. the comparison of results will be from two subject groups: * group a, the migraine suffering patient with or without aura * group b, the migraine suffering patient with or without aura who has diagnosed orthostatic intolerance (i.e.,feeling dizzy or faint when making a body position change).


Eligibility criteria:
inclusion criteria: * age 18 to 65 * male or female * migraine diagnosis * may or may not have orthostatic intolerance * able to demonstrate study understanding and complete informed consent process exclusion criteria: * subjects who do not meet inclusion criteria * subjects unable to complete informed consent process

Keywords: autonomic orthostatic syncope biopsy prevalence of autonomic dysfunction in migraineurs with orthostatic intolerance characterize autonomic findings utilizing neurocardiac testing, neurophysiological testing and skin biopsies to analyze autonomic fibers in the dermis
application of ultrasound technique in locating the end of the gastric tube in children aged 0-6 years

Conditions: Congenital Heart Disease

Summary: application of ultrasound technique to locate the end of the gastric tube in children aged 0-6 years

bedside blind insertion is the most common method for gastric tube indwelling in clinical practice. the key problem is that the position of the tube cannot be accurately determined in real time.bedside ultrasound has become a common medical technology, and resources are easy to obtain. therefore, bedside ultrasound has the advantages of fast, accurate, real-time repeatable, and non-invasive in determining the position of the end of the indwelling gastric tube.the purpose of this study is to investigate the accuracy of bedside ultrasound in guiding gastric tube placement and judging the position of the end of the tube in children with chd aged 0-6 years. to explore the feasibility and effectiveness of bedside ultrasound guided gastric tube placement during perioperative period in children with congenital heart disease (chd), this study plans to procedure the prospective randomized controlled study.

Eligibility criteria:
inclusion criteria: * children with chd who needed gastric tube in ccu were admitted * children aged 0-6 years * informed consent of parents exclusion criteria: * children with delayed sternal closure * the parents had cognitive impairment and mental disorders
retrospective study evaluating outcomes for integra® skin sheet products in lower extremity complex wounds

Conditions: Complex Lower Extremity Soft Tissue Reconstruction

Summary: this is a retrospective, multi-center study evaluating the outcomes of using integra® skin sheet bilayer or single layer products for complex soft tissue reconstruction of lower extremity diabetic wounds compared to other treatments. participating sites will collect information for all patients who received integra, free flap, local tissue flap, or negative pressure therapy over a 5 year period. the patient must be a minimum of 1 year from index procedure, with index procedure being defined as the application of integra, free flap, local tissue flap, or negative pressure. any follow-up occurring during the year is eligible for inclusion.


Eligibility criteria:
inclusion criteria: * diabetic (i or ii) male or female, age greater than 18 years * lower extremity wounds that required operative application of integra, free flap, local tissue flap, or negative pressure wound therapy. complex wounds are defined as wounds that involve exposed deep tissue (e.g. bone, tendon, fascia, ligament) * the patient must be a minimum of 1 year from the index procedure, any follow-up occurring during the year is eligible for inclusion. exclusion criteria: * age less than 18 years
coagulopathy of immunodermatologic diseases

Conditions: Autoimmune Bullous Dermatosis

Summary: this study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. blood samples will be collected from participants with active/poorly controlled immune-mediated skin diseases and mild/latent/well-controlled immune-mediated skin diseases. a one-time sample from 15 general dermatology outpatients who do not have a known or suspected diagnosis of bullous diseases, immune-mediated dermatologic condition, or cutaneous malignancy will also be collected to serve as control. blood samples from both participant populations will be analyzed for coagulation and inflammatory markers and compared. the results of this study may help inform future studies on the utility of analyzing coagulation and fibrinolysis profiles of patients with autoimmune skin diseases.

the purpose of this study is to examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. this will be accomplished by collecting blood samples from participants with both active/poorly controlled immune-mediated skin diseases and mild/latent/well-controlled immune-mediated skin diseases. a one-time sample will be collected from 15 general dermatology outpatients who do not have a known or suspected diagnosis of bullous diseases, immune-mediated dermatologic condition, or cutaneous malignancy to serve as the control population. blood samples from both participant populations will be analyzed for coagulation and inflammatory markers and compared. the results of this study may help inform future studies on the utility of analyzing coagulation and fibrinolysis profiles of patients with autoimmune skin diseases.

Eligibility criteria:
inclusion criteria: 1. for the study group: diagnosis of immune-mediated skin disease including but not limited to bullous pemphigoid, pemphigus vulgaris, mucous membrane pemphigoid, cutaneous lupus erythematosus, dermatomyositis 2. for control group: no diagnosis of immune-mediated skin 3. for study group: receiving care from one or more of the principal or secondary investigators exclusion criteria: 1. unfit to provide consent 2. p2y12 inhibitor use in the past 4 weeks 3. history of internal malignancy prior to enrolling in the study or suspected internal/systemic malignancy during time of the study (i.e. will not exclude pre-malignant or local, early stage cutaneous malignancies) 4. major surgery within 4 weeks of the study or trauma (e.g., accident-causing bone fracture) within 4 weeks of the study 5. other autoimmune diseases not in remission defined as flare in the last 12 weeks 6. if patient is unable to provide detailed history and if we do not have sufficient history on record. 7. less than 19 years of age
combined f-18 naf and f-18 fdg pet/ct for evaluation of malignancy

Conditions: Neoplasms

Summary: fluorine-18 fluorodeoxyglucose (f-18 fdg) pet/ct is established as a powerful imaging tool for cancer detection and monitoring response to therapy. sodium fluorine-18 (f-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current pet/ct scanners. the combined administration of f-18 and f-18 fdg in a single pet/ct scan for cancer detection was not attempted to date. we hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.


Eligibility criteria:
inclusion criteria: * patients older than 18-year-old, diagnosed with cancer * patients must understand and voluntarily sign an informed consent form after the contents have been fully explained to them exclusion criteria: * patients who cannot complete a pet/ct scan * pregnant women * healthy volunteers * patients participating in other research studies the subjects will not be paid to participate in this protocol. no costs will be charged to the subjects.
bobby™ balloon guide catheter for endovascular treatment of acute ischemic stroke

Conditions: Cerebrovascular Stroke

Summary: evaluation of the safety and performance of the bobby™ balloon guide catheter (bgc) in patients with an acute ischemic stroke treatment, a sudden reduction or termination of the blood circulation of the brain, caused by a clot. immediate treatment is needed to restore the blood circulation in the brain, performing a mechanical removal of the clot (thrombectomy). to prevent clot particles migrating in other parts of the brain circulation during the thrombectomy, balloon guiding catheters are inserted. the aim of the study is to evaluate the safety and performance of the balloon guide catheter bobby™ by collecting information from patients, treated with a mechanical thrombectomy and the balloon guide catheter (bobby™) after acute ischemic stroke

the main objective of the strait study is to assess the performance of the mechanical thrombectomy using a bobby™ balloon guide catheter (bgc) as adjunctive device for endovascular treatment of patients suffering from an anterior circulation acute ischemic stroke. interventional procedures and clinical follow-up will be performed per standard of care. patient health-related and imaging data will be collected as of stroke onset time up to 90 days follow up.

Eligibility criteria:
inclusion criteria: * patient is ≥ 18 and ≤ 85 years of age * informed consent by the patient or legal authorized representative for data collection is obtained * patient eligible for the mechanical thrombectomy treatment with adjunctive use of the bobby™ bgc * patient presenting with an anterior circulation large-vessel occlusion of distal internal carotic artery (ica ) through proximal m2 confirmed by computed tomograph angiography (cta), magnetic resonance angiography (mra), or digital subtraction angiography (dsa). * core-infarct volume of alberta stroke program early ct score (aspects) ≥ 6 based on baseline ct or mr imaging * treatment initiated (groin puncture) within 8 hours of symptom onset. * patient with a pre-treatment national institutes of health stroke scale (nihss) score ≥5 * patient with no personal condition disabling the site to contact him/her at 90 days after procedure exclusion criteria: * patient has evidence of cerebral ischemia in the posterior circulation * patient presents severe unilateral or bilateral carotid artery stenosis requiring stent treatment during the procedure * pregnancy or breastfeeding * patient presents other serious medical illness (e.g., cancer) with estimated life expectancy of less than 3 months * patient has a planned procedure that may cause non-compliance with the protocol or confound data interpretation * patient is already participating in an investigational drug or device trial (change routine care of the patient) * patient has evidence of intracerebral hemorrhage on initial imaging * patient has a significant mass effect with midline shift

Keywords: cerebrovascular stroke thrombectomy balloon guide catheter